Genor Biopharma Co. Ltd (“Genor”) is a biopharmaceutical powerhouse focusing on developing and commercializing oncology and autoimmune drugs. Genor has successfully developed drug candidates targeting pathways with blockbuster potentials, encompassing top three oncology targets and five out of the ten bestselling drugs globally. Genor has leveraged primarily in-house capabilities in establishing a pipeline of 15 targeted drug candidates with tremendous commercialization potentials in China that cover both proven and novel biological pathways.
Genor’s leadership team boasts more than 15 years of industry experience on average with proven track record and a well-balanced combination of expertise. Genor currently has around 400 employees across 3 sites in China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as lab in South San Francisco, US, among which 80% are R&D and clinical specialists.
Yuxi, Yunnan - Principally Phase 3 and commercial manufacturing
Zhangjiang, Shanghai - R&D center, QC/Analytical center, cGMP sample manufacturing
South San Francisco, US - Bi-specific platform
We aspire to become a biopharmaceutical company with global presence, serving patients and society.
Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally.
Shanghai Genor was incorporated in Shanghai, PRC
Yuxi Genor was incorporated in Yuxi, Yunnan, PRC
We completed the construction of manufacturing facilities in Yuxi, Yunnan, PRC
Our Company was incorporated in the Cayman Islands
Our Company completed Series A financing
Our Company completed Series B financing
Our submission of an NDA for GB226 as a monotherapy in r/r PTCL in the PRC was accepted by NMPA and granted priority review status